HeartWare International Inc

HeartWare International — American Heart Association Scientific Sessions 2010

16 slides from HeartWare International's conference presentation, Nov 15, 2010

  1. Slide 1: Evaluation of the HeartWare HVAD: Results of the ADVANCE Bridge to Transplant Trial

    Slide 1: Evaluation of the HeartWare HVAD: Results of the ADVANCE Bridge to Transplant Trial

    Keith Aaronson, Mark Slaughter, Edwin McGee, William Cotts, Michael Acker, Mariell Jessup, Igor Gregoric, Pranav Loyalka, Valluvan Jeevanandam, Allen Anderson, Robert Kormos, Jeffrey Teuteberg, Francis Pagani, Steven Boyce, David Hathaway, Leslie Miller for the HeartWare ADVANCE Investigators Evalua

  2. Slide 2: Presenter Disclosure Information

    Slide 2: Presenter Disclosure Information

    Presenter Disclosure Information Keith Aaronson, MD, MS FINANCIAL DISCLOSURE Research Support: HeartWare*, Thoratec*, Terumo Clinical Steering Committee: HeartWare Personal remuneration: none * My activities with HeartWare and Thoratec have been reviewed and approved by the University of Michigan Me

  3. Slide 3: HeartWare Ventricular Assist System

    Slide 3: HeartWare Ventricular Assist System

    HeartWare Ventricular Assist System HVAD miniaturized implantable blood pump Pericardial placement - no pump pocket Provides up to 10 L/min of flow Centrifugal design, continuous flow Hybrid magnetic / hydrodynamic impeller suspension Optimizes flow, pump surface washing, and hemocompatibility Thin

  4. Slide 4: ADVANCE Trial Design

    Slide 4: ADVANCE Trial Design

    Multi-site (30), prospective trial to evaluate the HeartWare HVAD as a bridge-to-transplant in the US Enrollment period was August 2008 to February 2010 All patients were followed for ^ 180 days following implant or until earlier cardiac transplantation, device explant for recovery or death Treatmen

  5. Slide 5: Derivation of Treatment & Control Populations

    Slide 5: Derivation of Treatment & Control Populations

    Adult patients who received a primary LVAD as a BTT during the enrollment period Listed for transplant at time of implant BSA ^ 1.2m2 Serum creatinine ^ 5 without dialysis Not on ventilator First VAD IABP only allowable preop circulatory support Treatment Group (n=137) Inclusion Criteria: age >18 ye

  6. Slide 6: ADVANCE Trial: Analyses

    Slide 6: ADVANCE Trial: Analyses

    Primary Outcome Success*, defined as survival on the originally implanted device, transplant or explant for ventricular recovery (must survive 60 days post- explant) at 180 days Analysis adjusted by propensity score Predictors: age, gender, BUN, creatinine, BSA, right atrial pressure, prior sternoto

  7. Slide 7: ADVANCE Trial: Baseline Characteristics

    Slide 7: ADVANCE Trial: Baseline Characteristics

    Control(n=499) P value 52.2 +- 12.2 0.19 120 (24%) 0.36 2.07 +- 0.3 0.59 28.9 +- 20.9 0.94 11.5 +- 5.0 0.53 1.4 +- 0.6 0.89 ADVANCE Trial: Baseline Characteristics

  8. Slide 8: Propensity Score and INTERMACS Patient Profile

    Slide 8: Propensity Score and INTERMACS Patient Profile

    Propensity Score INTERMACS Patient Profile * Safety Population (N=140) for INTERMACS Patient Profile; Per Protocol Population (N=137) for Propensity Score INTERMACS & Propensity Score

  9. Slide 9: ADVANCE Trial Primary Outcome: Success

    Slide 9: ADVANCE Trial Primary Outcome: Success

    Control Group Success: 90.1% Treatment Group Success: 92.0% Difference: -1.9% 95% Upper Confidence Limit (UCL) on difference 0.9% Principal Analysis: Noninferiority The UCL, 0.9%, is less than the prespecified 15% noninferiority margin. Treatment group success is noninferior to control (p<0.001) Sec

  10. Slide 10: ADVANCE Trial Treatment Group Outcomes (Per Protocol Population)

    Slide 10: ADVANCE Trial Treatment Group Outcomes (Per Protocol Population)

    Days Post Implant Proportion of Patients 62.8% Alive 29.2% Transplant 3.6% Death 4.4% Device Exchange 92.0% Transplant or Alive ADVANCE Trial Treatment Group Outcomes (Per Protocol Population) Patients at Risk 137 125 104 86 58 31 22 NOTE: Original device in place for all outcomes

  11. Slide 11: ADVANCE Trial Secondary Outcome: Survival

    Slide 11: ADVANCE Trial Secondary Outcome: Survival

    Days Post Implant % Survival Event: Death (censored at transplant or recovery) ITT Population Patients at Risk Treatment 140 128 108 92 63 36 26 Patients at Risk Control 499 440 370 305 228 176 127 ADVANCE Trial Secondary Outcome: Survival Days Post Implant Treatment Control 30 98.6% 96.6% 90 95.6%

  12. Slide 12: Quality of Life and Functional Capacity

    Slide 12: Quality of Life and Functional Capacity

    KCCQ KCCQ n = 79 Better QoL / Best Health Status Worst QoL/ Health Status 6 Min Walk Clinical Summary ^ Overall Summary 79 79 All paired differences p<0.001 EQ-5D VAS ^ = +77% ^ = +106% ^ = +91% ^ = +106% Quality of Life and Functional Capacity

  13. Slide 13: Adverse Events in Treatment Group (n = 140)

    Slide 13: Adverse Events in Treatment Group (n = 140)

    Pagani, et al.Event Rate PPY†† 0.45 Not reported 0.85 0.31 0.35 0.03 0.09 0.05 0.04 Adverse Events in Treatment Group (n = 140) Adverse Events in Treatment Group (n = 140) †† Pagani, et al. JACC 54: 312-321, 2009; 181.8 Patient-Years †87.47 Patient-Years 2 Five of 10 (50%) ischemic strokes occurred

  14. Slide 14: Adverse Events in Treatment Group (n = 140)

    Slide 14: Adverse Events in Treatment Group (n = 140)

    Pagani, et al. Event Rate PPY†† 0.40 0.09 0.20 0.14 0.06 0.04 0.48 0.17 0.07 †† Pagani, et al. JACC 54: 312-321, 2009; 181.8 Patient-Years †87.47 Patient-Years Adverse Events in Treatment Group (n = 140)

  15. Slide 15: ADVANCE Trial: Study Limitations

    Slide 15: ADVANCE Trial: Study Limitations

    Treatment assignment was not randomized and therefore relevant baseline characteristics may differ between groups Difficult to compare clinical trial outcomes to those of a national registry due to differences in data collection and adjudication Serial assessment of functional capacity and quality o

  16. Slide 16: ADVANCE Trial: Conclusions

    Slide 16: ADVANCE Trial: Conclusions

    Implantation of the small, continuous-flow HVAD pump contained in the pericardial space was associated with a high probability of success (92%) at 180 days HVAD pump demonstrated noninferiority to contemporaneously implanted, commercially available ventricular assist devices 1.4% 30-day mortality 94

Source: SEC EDGAR · 8-K filed Nov 15, 2010

More decks from HeartWare International Inc